{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T15:17:04Z","timestamp":1778253424838,"version":"3.51.4"},"reference-count":24,"publisher":"Walter de Gruyter GmbH","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_j.sjpain.2012.11.011_s_001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neuropathic pain remains a significant challenge with unsatisfactory therapeutic options. Its pathogenesis may involve the neuropathic triad of neuronal, glial and immune cells. Communication between these cells is possibly perpetuated by mitogen-activated protein kinase (MAPK)-signaling. For several years, we successfully treated a rectal cancer patient with the epithelial growth factor receptor (EGFR)-inhibitor cetuximab, for debilitating neuropathic pain due to progressive malignant invasion of the sacral plexus. Here, we report the effect of treatment with various EGFR-inhibitors in five additional patients with severe and long-standing, therapy-resistant neuropathic pain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_j.sjpain.2012.11.011_s_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All patients had well-documented neuropathic pain syndromes with the following etiologies: inflammatory polyneuropathy, complex regional pain syndrome type 1, radiculopathy after failed back surgery, malignant invasion of the sacral plexus by bladder cancer, and phantom limb pain. All patients were given intravenous (extracellular) EGFR-inhibitors (cetuximab, panitumumab) initially, and switched to oral (intracellular) agents (gefitinib, erlotinib) after an analgesic effect was obtained.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_j.sjpain.2012.11.011_s_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Four of the five patients responded, all within 24h of intravenous administration, with a mean decrease in worst pain from 9 to 1 on a 10-point scale. All four EGFR-inhibitors were effective. The clinical courses, including patient-reported pain relief, are prospectively documented with 78\u2013219 days follow-up for those who responded to treatment. Toxicities were transient and manageable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_j.sjpain.2012.11.011_s_004\">\n                    <jats:title>Conclusions\/implications<\/jats:title>\n                    <jats:p>EGFR-inhibition resulted in dramatic relief of neuropathic pain. A plausible biological explanation involves the interruption of MAPK-signaling. The role of EGFR-inhibition as a target for the treatment of neuropathic pain appears promising and warrants investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.sjpain.2012.11.011","type":"journal-article","created":{"date-parts":[[2013,1,10]],"date-time":"2013-01-10T17:18:46Z","timestamp":1357838326000},"page":"3-7","source":"Crossref","is-referenced-by-count":29,"title":["Epithelial growth factor receptor (EGFR)-inhibition for relief of neuropathic pain\u2013A case series"],"prefix":"10.1515","volume":"4","author":[{"given":"Christian","family":"Kersten","sequence":"first","affiliation":[{"name":"Center for Cancer Treatment , S\u00f8rlandet Hospital Trust , Serviceboks 416, 4604 Kristiansand , Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marte Gr\u00f8nlie","family":"Cameron","sequence":"additional","affiliation":[{"name":"Center for Cancer Treatment , S\u00f8rlandet Hospital Trust , Kristiansand , Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svein","family":"Mj\u00e5land","sequence":"additional","affiliation":[{"name":"Center for Cancer Treatment , S\u00f8rlandet Hospital Trust , Kristiansand , Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2013,1,1]]},"reference":[{"key":"2025120909543376032_j_j.sjpain.2012.11.011_ref_001","doi-asserted-by":"crossref","unstructured":"Jensen TS, Baron  R, Haanp\u00e4\u00e4 M, Kalso  E, Loeser JD, Rice AS, Treede RD. A new definition of neuropathic pain. Pain 2011;152:2204\u20135.","DOI":"10.1016\/j.pain.2011.06.017"},{"key":"2025120909543376032_j_j.sjpain.2012.11.011_ref_002","doi-asserted-by":"crossref","unstructured":"Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain 2010;150:573\u201381.","DOI":"10.1016\/j.pain.2010.06.019"},{"key":"2025120909543376032_j_j.sjpain.2012.11.011_ref_003","doi-asserted-by":"crossref","unstructured":"Jensen MP, Chodroff MJ, Dworkin RH. The impact of neuropathic pain on health-related quality of life: review and implications. Neurology 2007;68:1178\u201382.","DOI":"10.1212\/01.wnl.0000259085.61898.9e"},{"key":"2025120909543376032_j_j.sjpain.2012.11.011_ref_004","doi-asserted-by":"crossref","unstructured":"Dieleman JP, Kerklaan  J, Huygen FJ, Bouma PA, Sturkenboom MC. Incidence rates and treatment of neuropathic pain conditions in the general population. Pain 2008;137:681\u20138.","DOI":"10.1016\/j.pain.2008.03.002"},{"key":"2025120909543376032_j_j.sjpain.2012.11.011_ref_005","doi-asserted-by":"crossref","unstructured":"Bouhassira  D, Lant\u00e9ri-Minet  M, Attal  N, Laurent  B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2008;136:380\u20137.","DOI":"10.1016\/j.pain.2007.08.013"},{"key":"2025120909543376032_j_j.sjpain.2012.11.011_ref_006","doi-asserted-by":"crossref","unstructured":"Scholz  J, Woolf CJ. The neuropathic pain triad: neurons, immune cells and glia. Nat Neurosci 2007;10:1361\u20138.","DOI":"10.1038\/nn1992"},{"key":"2025120909543376032_j_j.sjpain.2012.11.011_ref_007","doi-asserted-by":"crossref","unstructured":"Ji RR, Gereau RW 4th, Malcangio  M, Strichartz GR. MAP kinase and pain. Brain Res Rev 2009;60:135\u201348.","DOI":"10.1016\/j.brainresrev.2008.12.011"},{"key":"2025120909543376032_j_j.sjpain.2012.11.011_ref_008","doi-asserted-by":"crossref","unstructured":"Kersten  C, Cameron MG. Cetuximab alleviate sneuropathic pain despite tumour progression. BMJ Case Rep 2012;2012.","DOI":"10.1136\/bcr.12.2011.5374"},{"key":"2025120909543376032_j_j.sjpain.2012.11.011_ref_009","doi-asserted-by":"crossref","unstructured":"Yarden  Y, Pines G. The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer 2012;12:553\u201363.","DOI":"10.1038\/nrc3309"},{"key":"2025120909543376032_j_j.sjpain.2012.11.011_ref_010","doi-asserted-by":"crossref","unstructured":"Freynhagen  R, Baron  R, Gockel  U, T\u00f6lle TR. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006;22:1911\u201320.","DOI":"10.1185\/030079906X132488"},{"key":"2025120909543376032_j_j.sjpain.2012.11.011_ref_011","doi-asserted-by":"crossref","unstructured":"Klepstad  P, Loge JH, Borchgrevink PC, Mendoza TR, Cleeland CS, Kaasa S. The Norwegian brief pain inventory questionnaire: translation and validation in cancer pain patients. J Pain Symptom Manage 2002;24:517\u201325.","DOI":"10.1016\/S0885-3924(02)00526-2"},{"key":"2025120909543376032_j_j.sjpain.2012.11.011_ref_012","doi-asserted-by":"crossref","unstructured":"Keller  S, Bann CM, Dodd SL, Schein  J, Mendoza TR, Cleeland CS. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain 2004;20:309\u201318.","DOI":"10.1097\/00002508-200409000-00005"},{"key":"2025120909543376032_j_j.sjpain.2012.11.011_ref_013","doi-asserted-by":"crossref","unstructured":"Feinstein TM, Gibson MK, Argiris A. Cetuximab-induced aseptic meningitis. Ann Oncol 2009;20:1609\u201310.","DOI":"10.1093\/annonc\/mdp382"},{"key":"2025120909543376032_j_j.sjpain.2012.11.011_ref_014","doi-asserted-by":"crossref","unstructured":"Basti S. Ocular toxicities of epidermal growth factor receptor inhibitors and their management. Cancer Nurs 2007;30(Suppl. 1):S10\u20136.","DOI":"10.1097\/01.NCC.0000281759.23823.82"},{"key":"2025120909543376032_j_j.sjpain.2012.11.011_ref_015","doi-asserted-by":"crossref","unstructured":"Ramanathan RK. Alternative dosing schedules for cetuximab: a role for biweekly administration? Clin Colorectal Cancer 2008;7:364\u20138.","DOI":"10.3816\/CCC.2008.n.048"},{"key":"2025120909543376032_j_j.sjpain.2012.11.011_ref_016","doi-asserted-by":"crossref","unstructured":"Saadeh CE, Lee HS. Panitumumab: a fully human monoclonal antibody with activity in metastatic colorectal cancer. Ann Pharmacother 2007;41:606\u201313.","DOI":"10.1345\/aph.1H492"},{"key":"2025120909543376032_j_j.sjpain.2012.11.011_ref_017","doi-asserted-by":"crossref","unstructured":"Alvarenga ML, Kikhney  J, Hannewald  J, Metzger AU, Steffens KJ, Bomke  J, Krah  A, Wegener A. In-depth biophysical analysis of interactions between therapeutic antibodies and the extracellular domain of the epidermal growth factor receptor. Anal Biochem 2012;421:138\u201351.","DOI":"10.1016\/j.ab.2011.10.039"},{"key":"2025120909543376032_j_j.sjpain.2012.11.011_ref_018","doi-asserted-by":"crossref","unstructured":"Ma  F, Zhang  L, Westlund KN. Trigeminal nerve injury ErbB3\/ErbB2 promotes mechanical hypersensitivity. Anesthesiology 2012;117(2):381\u20138.","DOI":"10.1097\/ALN.0b013e3182604b2b"},{"key":"2025120909543376032_j_j.sjpain.2012.11.011_ref_019","doi-asserted-by":"crossref","unstructured":"Yasuda  S, Sugiura  H, Tanaka  H, Takigami  S, Yamagata K. p38 MAP kinase inhibitors as potential therapeutic drugs for neural diseases. Cent Nerv Syst Agents Med Chem 2011;11:45\u201359.","DOI":"10.2174\/187152411794961040"},{"key":"2025120909543376032_j_j.sjpain.2012.11.011_ref_020","doi-asserted-by":"crossref","unstructured":"Liu  B, Neufeld AH. Activation of epidermal growth factor receptors in astrocytes: from development to neural injury. J Neurosci Res 2007;85:3523\u20139.","DOI":"10.1002\/jnr.21364"},{"key":"2025120909543376032_j_j.sjpain.2012.11.011_ref_021","doi-asserted-by":"crossref","unstructured":"Carroll SL, Miller ML, Frohnert PW, Kim SS, Corbett JA. Expression of neuregulins and their putative receptors, ErbB2 and ErbB3, is induced during Wallerian degeneration. J Neurosci 1997;17:1642\u201359.","DOI":"10.1523\/JNEUROSCI.17-05-01642.1997"},{"key":"2025120909543376032_j_j.sjpain.2012.11.011_ref_022","doi-asserted-by":"crossref","unstructured":"Calvo  M, Zhu  N, Grist  J, Ma  Z, Loeb JA, Bennett DL. Following nerve injury neuregulin-1 drives microglial proliferation and neuropathic pain via the MEK\/ERK pathway. Glia 2011;59:554\u201368.","DOI":"10.1002\/glia.21124"},{"key":"2025120909543376032_j_j.sjpain.2012.11.011_ref_023","doi-asserted-by":"crossref","unstructured":"Kanzaki  H, Mizobuchi  S, Obata  N, Itano  Y, Kaku  R, Tomotsuka  N, Nakajima  H, Ouchida  M, Nakatsuka  H, Maeshima  K, Morita K. Expression changes of the neuregulin 1 isoforms in neuropathic pain model rats. Neurosci Lett 2012;508:78\u201383.","DOI":"10.1016\/j.neulet.2011.12.023"},{"key":"2025120909543376032_j_j.sjpain.2012.11.011_ref_024","unstructured":"Oliveras-Ferraros  C, Vazquez-Martin  A, Queralt  B, Adrados  M, Ortiz  R, Cuf\u00ed S, Hern\u00e1ndez-Yag\u00fce X, Guarden\u02dco R, B\u00e1ez L, Martin-Castillo  B, P\u00e9rez-Mart\u00ednez MC, Lopez-Bonet  E, De Llorens  R, Bernad\u00f3 L, Brunet  J, Menendez JA. Interferon\/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux(R)) efficacy in KRAS wild-type squamous carcinomas: a pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models. Int J Oncol 2011;39:1455\u201379."}],"container-title":["Scandinavian Journal of Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/sjpain\/4\/1\/article-p3.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1877886012002078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1877886012002078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1016\/j.sjpain.2012.11.011\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1016\/j.sjpain.2012.11.011\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:44:02Z","timestamp":1765280642000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1016\/j.sjpain.2012.11.011\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,1]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013,1,1]]},"published-print":{"date-parts":[[2013,1,1]]}},"alternative-id":["10.1016\/j.sjpain.2012.11.011"],"URL":"https:\/\/doi.org\/10.1016\/j.sjpain.2012.11.011","relation":{},"ISSN":["1877-8860","1877-8879"],"issn-type":[{"value":"1877-8860","type":"print"},{"value":"1877-8879","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,1]]}}}